Skip to content

Quest Diagnostics DGX Free cash flow

Free cash flow at other companies

Opko Health logo
Opko HealthOPK
-$21.14M+44.0%
NeoGenomics logo
NeoGenomicsNEO
-$13.14M+56.0%
Exagen Inc. logo
Exagen Inc.XGN
-$10.65M+1.3%
Personalis, Inc. logo
Personalis, Inc.PSNL
-$25.67M-25.4%
Sera Prognostics logo
Sera PrognosticsSERA
-$8.78M-16.2%
Labcorp Holdings logo
Labcorp HoldingsLH

Other financials

Income statement

See full
Revenue$2.9B+9.2%
Gross profit$942.0M+9.2%
Operating income$399.0M+15.3%
Net income$252.0M+14.5%
EPS (diluted)$2.24+15.5%

Balance sheet

See full
Cash & equivalents$393.0M+109%
Total debt$6.4B-2.5%
Total equity$7.4B+6.3%
Total assets$16.7B+5.5%

Cash flow

See full
Operating cash flow$278.0M-11.5%
CapEx$114.0M-2.6%

Valuation

See full
Market cap$23.46B+20.8%
Enterprise value$29.48B+15.7%
P/E22.9×+2.5×
P/S2.1×+0.2×

Profitability

See full
Gross margin33.2%+0.4pp
Operating margin14.3%+0.6pp
Net margin9.1%+0.2pp
FCF margin11.8%+1.4pp

Returns & leverage

See full
Return on equity14.3%+0.9pp
Debt / equity0.9×-0.1×
Current ratio1.2×-0.3×

Where this comes from

Calculated from Quest Diagnostics’s reported figures.

The official record: Quest Diagnostics’s 10-Q, filed April 22, 2026, on SEC EDGAR. View the filing →

Ask your AI about Quest Diagnostics's free cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Quest Diagnostics's free cash flow?
Quest Diagnostics (DGX) reported free cash flow of $164M in Q1 2026.
How has Quest Diagnostics's free cash flow changed year-over-year?
Quest Diagnostics's free cash flow decreased by 16.8% year-over-year, from $197M to $164M.
What is the long-term trend for Quest Diagnostics's free cash flow?
Over 4 years (2021 to 2025), Quest Diagnostics's free cash flow has grown at a -7.2% compound annual growth rate (CAGR), from $1.83B to $1.36B.
What does free cash flow mean?
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.